Discover
DYN
Dyne Therapeutics, Inc.
17.11
2 x 12.86
2 x 21.76
bid
ask
-
0.95
5.26%
2 @ 07:30 PM
17.06 -0.05 (0.29%)
| Ytd | -12.53% | |
| 1y | 22.92% |
16.96
day range
18.14
12.37
52 week range
26.78
| Open | 18.07 | Prev Close | 18.06 | Low | 16.96 | High | 18.14 | Mkt Cap | 3.20B |
| Vol | 4.85M | Avg Vol | 2.63M | EPS | -3.26 | P/E | N/A | Forward P/E | -5.13 |
| Beta | 1.08 | Short Ratio | 11.68 | Inst. Own | 103.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 24.12 | 200-d Avg | 19.82 | 1yr Est | 37.20 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.88 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -0.75 | -1.08 | -0.33 | -44.23% |
| 2026-05-11 | 2026-03 | -0.77 | -0.73 | 0.04 | 5.48% |
| 2026-03-02 | 2025-12 | -0.74 | -0.76 | -0.02 | -2.70% |
| 2025-11-05 | 2025-09 | -0.81 | -0.76 | 0.05 | 6.17% |
| 2025-07-28 | 2025-06 | -0.99 | -0.97 | 0.02 | 2.02% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-09 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-09-09 | JP Morgan | Downgrade | Neutral | Underweight |
| 2026-09-09 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-09-09 | Baird | Upgrade | Outperform | Outperform |
| 2026-07-31 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-07-30 | RBC Capital | Upgrade | Outperform | Outperform |
Profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-10 | BESKROVNAYA OXANA | Officer | 195.84K | Sale |
| 2026-09-07 | COX JOHN | Chief Executive Officer | 429.51K | Sale |
| 2026-09-07 | FRIEDL-NADERER JOHANNA | Officer | 152.90K | Sale |
| 2026-09-07 | KERR DOUGLAS | Officer | 162.56K | Sale |
| 2026-07-26 | KERSTEN DIRK | Director | 0.00 | Sale |
| 2026-04-23 | LUBNER DAVID CHARLES | Director | 0.00 | Stock Gift |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | T. Rowe Price Investment Management, Inc. | 30.91M | 528.91M | 16.55% |
| 2026-06-29 | Blackrock Inc. | 12.40M | 212.24M | 6.64% |
| 2026-06-29 | Jupiter Topco LLC | 12.00M | 205.28M | 6.42% |
| 2026-06-29 | FMR, LLC | 11.21M | 191.75M | 6.00% |
| 2026-06-29 | State Street Corporation | 7.46M | 127.61M | 3.99% |
| 2026-06-29 | Orbis Allan Gray Ltd | 7.01M | 119.88M | 3.75% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | T. Rowe Price Small-Cap Stock Fund, Inc. | 7.00M | 119.85M | 3.75% |
| 2026-06-29 | T. Rowe Price Small-Cap Value Fund, Inc. | 4.60M | 78.75M | 2.46% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.47M | 76.51M | 2.39% |
| 2026-07-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.07M | 69.59M | 2.18% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 ETF | 3.83M | 65.49M | 2.05% |
| 2026-06-29 | T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.81M | 65.18M | 2.04% |